HCA Healthcare, Inc.

HCA Healthcare's capital structure is highly leveraged, with a debt-to-equity ratio of -7.01, indicating a significant reliance on debt financing. The company's liquidity position is strained, as evidenced by a current ratio of 0.83, where current liabilities exceed current assets. Despite this, the company generates positive operating cash flow of $2.014 billion and free cash flow of $895 million, which supports ongoing operations and debt servicing. Profitability metrics show mixed results. The company's return on assets (ROA) is 2.64%, which is in line with industry norms, but its return on equity (ROE) is negative at -25.7%, primarily due to its negative equity position. This suggests that while the company is generating returns on its asset base, it is not effectively leveraging equity to generate returns for shareholders. HCA Healthcare's revenue is concentrated across 19 U.S. states and the United Kingdom, with a diversified portfolio of 190 facilities, including 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals. The company's geographic exposure is broad, but its operations are heavily concentrated in the U.S., which may expose it to regional healthcare policy changes and economic fluctuations. The company's growth trajectory is supported by a strong revenue base of $19.109 billion in Q1 2026, with positive free cash flow and capital expenditures of $1.119 billion indicating ongoing investment in infrastructure. Analysts have a generally positive outlook, with a mean price target of $508.46 and a median of $515.00, suggesting confidence in the company's ability to maintain or grow its market position. HCA Healthcare faces several risk factors, including liquidity constraints and potential dilution. The company's current liabilities exceed current assets, and its net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. However, the risk of dilution is assessed as low, and no significant adjustments have been applied to the valuation metrics. Recent filings highlight ongoing legal and regulatory proceedings that could have a material adverse effect on the company's operations and liquidity. The company also faces competition for patients and potential changes in physician utilization practices that could impact demand for its services. These factors underscore the importance of monitoring the company's legal exposure and market dynamics.